FR09C0041I2 - - Google Patents

Info

Publication number
FR09C0041I2
FR09C0041I2 FR09C0041C FR09C0041C FR09C0041I2 FR 09C0041 I2 FR09C0041 I2 FR 09C0041I2 FR 09C0041 C FR09C0041 C FR 09C0041C FR 09C0041 C FR09C0041 C FR 09C0041C FR 09C0041 I2 FR09C0041 I2 FR 09C0041I2
Authority
FR
France
Prior art keywords
pain
inflammatory
chronic
analgesics
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR09C0041C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8176844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR09C0041(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schwarz Pharma AG filed Critical Schwarz Pharma AG
Publication of FR09C0041I1 publication Critical patent/FR09C0041I1/fr
Application granted granted Critical
Publication of FR09C0041I2 publication Critical patent/FR09C0041I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR09C0041C 2001-03-20 2009-09-07 Active FR09C0041I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01106891A EP1243262B1 (fr) 2001-03-20 2001-03-20 Nouvelle utilisation d'un composé peptidique pour le traitement de la douleur inflammatoire non-neuropathique
EP02727437A EP1373300B1 (fr) 2001-03-20 2002-03-19 Nouvelle utilisation d'une classe de composes peptidiques pour le traitement de douleurs inflammatoires non neuropathiques
PCT/EP2002/003034 WO2002074784A2 (fr) 2001-03-20 2002-03-19 Nouvelle utilisation d'une classe de composes peptidiques pour le traitement de douleurs inflammatoires non neuropathiques

Publications (2)

Publication Number Publication Date
FR09C0041I1 FR09C0041I1 (fr) 2009-10-30
FR09C0041I2 true FR09C0041I2 (fr) 2010-01-22

Family

ID=8176844

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0041C Active FR09C0041I2 (fr) 2001-03-20 2009-09-07

Country Status (30)

Country Link
US (3) US6803481B2 (fr)
EP (2) EP1243262B1 (fr)
JP (1) JP4955906B2 (fr)
KR (1) KR100773100B1 (fr)
CN (2) CN100415225C (fr)
AT (2) ATE327744T1 (fr)
AU (1) AU2002257681C1 (fr)
BR (1) BR0205823A (fr)
CA (1) CA2419397C (fr)
CY (3) CY1105533T1 (fr)
CZ (1) CZ20032763A3 (fr)
DE (3) DE60120104T2 (fr)
DK (2) DK1243262T3 (fr)
EA (1) EA007532B1 (fr)
ES (2) ES2262567T3 (fr)
FR (1) FR09C0041I2 (fr)
HU (1) HUP0303600A3 (fr)
IL (2) IL154087A0 (fr)
LU (1) LU91590I2 (fr)
MX (1) MXPA03008467A (fr)
NL (1) NL300399I1 (fr)
NO (1) NO20033629L (fr)
NZ (1) NZ523865A (fr)
PL (1) PL216213B1 (fr)
PT (2) PT1243262E (fr)
SI (2) SI1373300T1 (fr)
SK (1) SK287539B6 (fr)
UA (1) UA82645C2 (fr)
WO (1) WO2002074784A2 (fr)
ZA (1) ZA200300858B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8676301A (en) * 2000-08-25 2002-03-04 Res Corp Technologies Inc New uses for amino acid anticonvulsants
DK1243262T3 (da) * 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
ES2185606T3 (es) * 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
JP4664924B2 (ja) * 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (fr) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Nouvelle utilisation de peptides pour le traitement de la neuropathie diabètique
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
KR20070007931A (ko) * 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604654A1 (fr) 2004-05-18 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement des dyskynesies
EP1604655A1 (fr) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de neuralgies trigeminales
EP1604656A1 (fr) 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de la sclérose amytrophique latérale (ALS)
US7427601B2 (en) 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
PL1781276T3 (pl) * 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
EP1642889A1 (fr) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Route de synthèse améliorée pour lacosamide
KR20070096058A (ko) 2005-01-28 2007-10-01 쉬바르츠파르마에이지 정신분열증의 부가 요법용 ｓｐｍ 927
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (fr) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) pour le traitement de la myalgie, par exemple de la fibromyalgie
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
JP2009539792A (ja) * 2006-06-08 2009-11-19 シュヴァルツ・ファーマ・アーゲー 疼痛の医学的状態のための治療組合せ
EP1873527A1 (fr) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Procédé d'identification des modulateurs CRMP
EP1920780A1 (fr) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Composés peptidiques pour le traitement des maladies liées à l'hyperexcitabilité
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
WO2007144195A2 (fr) 2006-06-15 2007-12-21 Schwarz Pharma Ag Composition pharmaceutique ayant un effet anticonvulsivant synergique
CA2774569A1 (fr) * 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Nouveaux derives a substitution n-benzylamide d'acide 2-(acylamido)acetique et d'acides 2-(acylamido)propioniques: agents neurologiques puissants
MX2013005974A (es) 2010-12-02 2013-07-29 Ucb Pharma Gmbh Formulacion de lacosamida de administracion una vez al dia.
EP2468261A1 (fr) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation de lacosamide
GB2491118B (en) 2011-05-20 2015-12-30 Otsuka Pharma Co Ltd Cannabinoids for use in the treatment of neuropathic pain
DK2858496T3 (da) * 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2937698A1 (de) 1979-09-18 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4533657A (en) 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
FR2518088B1 (fr) 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US4510082A (en) 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
JPH0680079B2 (ja) 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5656267A (en) * 1991-08-22 1997-08-12 Sagen; Jacqueline Implantable cells that alleviate chronic pain in humans
TW217417B (fr) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
US5278729A (en) * 1992-04-10 1994-01-11 Magnavox Electronic Systems Company Compact rotatable electrical device
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
EP0905126B1 (fr) * 1994-01-22 2002-12-04 British Biotech Pharmaceuticals Limited Inhibiteurs de métalloprotéinase
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5536853A (en) 1994-04-11 1996-07-16 Chiron Corporation Opiate receptor ligands
MY113062A (en) * 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5508266A (en) 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
CZ288436B6 (en) 1994-10-05 2001-06-13 Darwin Discovery Ltd Peptidyl derivatives, their therapeutic use as inhibitors of metalloproteinases and pharmaceutical preparation in which they are comprised
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5780589A (en) 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US5760038A (en) 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5849737A (en) 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
EP0840612A1 (fr) 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition de l'activite des recepteurs du n-methyl-d-aspartate au moyen de derives de sulfate de pregnenolone
US6114390A (en) 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19614542A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE19636046A1 (de) 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5866585A (en) 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
AU7937298A (en) 1997-07-08 1999-02-08 Ono Pharmaceutical Co. Ltd. Amino acid derivatives
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
WO1999007413A1 (fr) * 1997-08-11 1999-02-18 Algos Pharmaceutical Corporation Inhibiteurs de la substance p associes a des inhibiteurs nmda pour traiter la douleur
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
WO1999023078A2 (fr) 1997-10-31 1999-05-14 Basf Aktiengesellschaft Nouveaux derives d'acide carboxylique, portant des chaines laterales amidees; leur mode de production et leur utilisation en tant qu'antagonistes recepteurs d'endotheline
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
EP1137642B1 (fr) 1999-09-03 2007-12-05 Actelion Pharmaceuticals Ltd. Bis-sulfonamides
SE0001373D0 (sv) * 2000-04-13 2000-04-13 Karolinska Innovations Ab NPY Y1 receptor agonists and antagonists
DK1311256T3 (da) 2000-08-17 2005-11-28 Teva Pharma Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
AU8676301A (en) * 2000-08-25 2002-03-04 Res Corp Technologies Inc New uses for amino acid anticonvulsants
AU2002224847A1 (en) 2000-11-21 2002-06-03 U C B, S.A. N-alkylated gaba compounds, processes for their preparation and their use as medicaments
DK1243262T3 (da) * 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
ES2185606T3 (es) 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
IL157093A0 (en) 2001-03-27 2004-02-08 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
CA2445290A1 (fr) 2001-04-26 2002-11-07 Chenkou Wei Comprime pharmaceutique a haute teneur en ingredient pharmaceutique actif
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
AU2003243180A1 (en) 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
ATE361289T1 (de) 2002-08-05 2007-05-15 Lilly Co Eli Piperazinsubstituierte arylbenzodiazepine
WO2004043926A1 (fr) 2002-11-11 2004-05-27 Bayer Healthcare Ag Derives de phenyl- ou heteroarylamino-alcanes comme antagonistes du recepteur ip
CA2544467C (fr) 2002-11-18 2014-02-18 John M. Stewart Peptide paralytique utilisable dans un traitement neuromusculaire
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
EP1575563B1 (fr) 2002-12-19 2007-02-14 Pharmacia Corporation Formulation a caractere non-hygroscopique comprenant un principe actif hydroscopique
WO2004066987A2 (fr) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methodes destinees a traiter les troubles du tractus gastro-intestinal au moyen de modulateurs du canal sodique
AU2004207010A1 (en) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
WO2004100871A2 (fr) 2003-05-09 2004-11-25 Pharmacia Corporation Combinaison d'un antagoniste du recepteur de l'aldosterone et d'un inhibiteur de renine
US7320675B2 (en) 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
JP4664924B2 (ja) 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
EP1537862A1 (fr) 2003-12-02 2005-06-08 Schwarz Pharma Ag Nouvelle utilisation de peptides pour le traitement de la douleur neuropathique centrale
EP1541138A1 (fr) 2003-12-05 2005-06-15 Schwarz Pharma Ag Nouvelle utilisation de peptides pour le traitement de la status epilepticus et etats connexes
US20060009384A1 (en) 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (fr) 2004-03-26 2005-09-28 Schwarz Pharma Ag Nouvelle utilisation de peptides pour le traitement de la neuropathie diabètique
US20050227961A1 (en) 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
KR20070007931A (ko) 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604654A1 (fr) 2004-05-18 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement des dyskynesies
EP1604655A1 (fr) 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de neuralgies trigeminales
EP1604656A1 (fr) 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de la sclérose amytrophique latérale (ALS)
US7427601B2 (en) 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
PL1781276T3 (pl) 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
EP1642889A1 (fr) 2004-10-02 2006-04-05 Schwarz Pharma Ag Route de synthèse améliorée pour lacosamide
US20060252749A1 (en) 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1688137A1 (fr) 2005-01-28 2006-08-09 Schwarz Pharma Ag SPM 927 pour la thérapie adjuvante de la schizophrenie
US20070048372A1 (en) 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (fr) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) pour le traitement de la myalgie, par exemple de la fibromyalgie

Also Published As

Publication number Publication date
CN101332292A (zh) 2008-12-31
CN101332292B (zh) 2012-06-20
BR0205823A (pt) 2003-10-21
HK1058368A1 (en) 2004-05-14
KR100773100B1 (ko) 2007-11-02
WO2002074784A2 (fr) 2002-09-26
EA007532B1 (ru) 2006-10-27
JP4955906B2 (ja) 2012-06-20
WO2002074784A3 (fr) 2002-11-21
US20050085423A1 (en) 2005-04-21
US8053476B2 (en) 2011-11-08
DK1243262T3 (da) 2006-10-02
CY1105533T1 (el) 2010-07-28
SK287539B6 (sk) 2011-01-04
PL216213B1 (pl) 2014-03-31
UA82645C2 (uk) 2008-05-12
SI21170A (sl) 2003-10-31
CN100415225C (zh) 2008-09-03
NO20033629D0 (no) 2003-08-15
PT1373300E (pt) 2009-07-22
HUP0303600A2 (hu) 2004-03-01
EP1373300B1 (fr) 2009-05-20
US6803481B2 (en) 2004-10-12
ES2262567T3 (es) 2006-12-01
CZ20032763A3 (cs) 2004-01-14
CY2009013I2 (el) 2012-01-25
CY2009013I1 (el) 2012-01-25
SI1373300T1 (sl) 2009-10-31
US20030171300A1 (en) 2003-09-11
PT1243262E (pt) 2006-10-31
FR09C0041I1 (fr) 2009-10-30
EP1243262B1 (fr) 2006-05-31
IL154087A (en) 2010-05-17
ZA200300858B (en) 2003-07-09
US20070054962A1 (en) 2007-03-08
ATE327744T1 (de) 2006-06-15
AU2002257681C1 (en) 2008-02-21
MXPA03008467A (es) 2003-12-08
DE122009000053I1 (de) 2010-05-27
EP1373300A2 (fr) 2004-01-02
NZ523865A (en) 2004-12-24
HUP0303600A3 (en) 2011-11-28
IL154087A0 (en) 2003-07-31
ES2326627T3 (es) 2009-10-16
EA200300932A1 (ru) 2004-04-29
CN1498103A (zh) 2004-05-19
EP1243262A1 (fr) 2002-09-25
DK1373300T3 (da) 2009-08-31
AU2002257681A2 (en) 2002-10-03
SK12832003A3 (sk) 2004-02-03
CA2419397C (fr) 2009-09-15
CA2419397A1 (fr) 2002-09-26
KR20040004369A (ko) 2004-01-13
PL362985A1 (en) 2004-11-15
NO20033629L (no) 2003-08-15
CY1109308T1 (el) 2012-01-25
DE60120104T2 (de) 2006-09-21
DE60232407D1 (de) 2009-07-02
AU2002257681B2 (en) 2007-06-07
DE60120104D1 (de) 2006-07-06
LU91590I2 (fr) 2009-10-05
ATE431833T1 (de) 2009-06-15
NL300399I1 (en) 2009-10-01
JP2004524340A (ja) 2004-08-12

Similar Documents

Publication Publication Date Title
FR09C0041I2 (fr)
WO2006122186A3 (fr) Derives de 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone utilises dans le traitement de l'hypercholesterolemie
MXPA04001891A (es) Inhibidores policiclicos de guanina fosfodiesterasa v.
IL172773A (en) Formulations for the treatment of arthritis conditions
HUP0301828A3 (en) Use of apomorphine for the production of pharmaceutical compositions for treating sexual dysfunction with apomorphine at specified plasma concentration levels
NL1019899A1 (nl) Verwijdering van onzuiverheden uit koolwaterstofstromen.
ATE405834T1 (de) Bindungsoberfläche
WO2003093242A3 (fr) Composes polycycliques a 5 elements substitues pour l'inhibition selective de la cascade de reactions dans la coagulation sanguine
WO2002070457A8 (fr) Inhibiteur de la capture de la monoamine
ATE508121T1 (de) Derivate von hydroxamsäure als metalloproteinaseinhibitoren
EP1498501A4 (fr) Procede de production d'acier martensitique inoxydable
FR2875510B1 (fr) Procede de traitement pour inhiber la corrosion de voute de pipes utilises dans l'industrie petroliere
EA200401339A1 (ru) Нитрозированные имидазопиридины
WO2002064742A3 (fr) Composes effectuant une remodelisation neuronale et tests pour ces composes
BR9913140A (pt) Derivados 2-oxo-2h-quinolina
FR2821346B1 (fr) Procede de denitrification d'eaux usees
TH66369A (th) เบนซิมิดาโซลที่มีประโยชน์ในการบำบัดความบกพร่องทางเพศ